Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1600 participants.
Also called NCT03795298
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 1,600 participants
- Sponsor
- Registry
-
NCT03795298
-
- Other papers using this trial's data
- Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
- Percutaneous left atrial appendage closure following catheter ablation therapy of atrial fibrillation: outcomes stratified by bleeding risk - a sub-analysis of the OPTION study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Denmark, France, Germany, Italy, Netherlands, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03795298. Randomized; no masking; primary purpose prevention. Start 2019-05-20 (actual); primary completion 2024-07-24 (actual). Results posted on 2025-09-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
- Acronym
- OPTION
- Condition
- Atrial Fibrillation
- Intervention (Device)
- WATCHMAN FLX Implant
- Intervention (Drug)
- Market-approved OAC
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct03795298- Content hash
5e9d405464d8d575d530623b09ff64769184d68006a856ef1023a163e5625f89